BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ensacove (Ensartinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ensacove (Ensartinib)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06762327-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06762327)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2.\nStudy: Ensartinib in the Trea
 tment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Exclud
 ed Lung Cancer\nEstimated primary completion: 30 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ensartinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06762327
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03420508-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT03420508)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2.\nStudy: Treating Patients With
  Melanoma and ALK Alterations With Ensartinib\nEstimated primary completio
 n: January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ensa
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03420508
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05241028-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT05241028)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-sm
 all Cell Lung Cancer\nEstimated primary completion: February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ensartinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05241028
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04837716-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Ensacove (Ensartinib): Phase 1 readout est. (NCT04837716)
DESCRIPTION:Ensacove (Ensartinib)\, phase 1\, Non-Small Cell Lung Cancer.\n
 Study: Ensartinib\, Carboplatin\, Pemetrexed and Bevacizumab for the Treat
 ment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Can
 cer\nEstimated primary completion: 23 September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ensartinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04837716
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06563999)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III
  NSCLC Harboring Rare Mutations.\nEstimated primary completion: 1 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ensartinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0656399
 9
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354061-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Ensacove (Ensartinib): Phase 1/2 readout est. (NCT07354061)
DESCRIPTION:Ensacove (Ensartinib)\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy fo
 r ALK-positive Non - Small Cell Lung Cancer (NSCLC)\nEstimated primary com
 pletion: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ensartinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07354061
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06779539-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06779539)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III N
 on-Small Cell Lung Cancer\nEstimated primary completion: 12 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ensartinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06779539
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671560-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ensacove (Ensartinib): Phase 4 readout est. (NCT07671560)
DESCRIPTION:Ensacove (Ensartinib)\, phase 4\, Non-Small Cell Lung Cancer.\n
 Study: Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlat
 inib-Resistant ALK-Positive NSCLC\nEstimated primary completion: 31 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ensartinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07671
 560
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780839-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06780839)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with 
 Ensartinib Guided by MRD\nEstimated primary completion: 15 January 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ensartinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06780839
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448116-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Ensacove (Ensartinib): Phase 1/2 readout est. (NCT07448116)
DESCRIPTION:Ensacove (Ensartinib)\, phase 1/2.\nStudy: Study of MCLA-129 in
  Combination With Ensartinib in Patients With Advanced Solid Tumors.\nEsti
 mated primary completion: 1 February 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ensartinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07448116
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772610-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06772610)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage 
 I ALK-positive NSCLC Patients with High Risk Factors\nEstimated primary co
 mpletion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ensartinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06772610
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06955325-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Ensacove (Ensartinib): Phase 3 readout est. (NCT06955325)
DESCRIPTION:Ensacove (Ensartinib)\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk
  Stage IA-IB NSCLC: Focus on Driver Mutations\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ens
 artinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06955325
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235306-1978@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT07235306)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC\n
 Estimated primary completion: 31 January 2031. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ensartinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07235306
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
